GOMOZIGOTNAYa MUTATsIYa V GENE INGIBITORA AKTIVATORA PLAZMINOGENA 1 U PATsIENTOV S ANTIFOSFOLIPIDNYM SINDROMOM
https://doi.org/10.14412/1995-4484-2011-1465
Abstract
Antifosfolipidnyi sindrom (AFS) – simptomo- kompleks, proyavlyayushchiisya trombozom sosudov razlichnoi lokalizatsii i kalibra pri obyazatel'nom nalichii v krovi antifosfolipidnykh antitel (aFL) [1]. K serologicheskim markeram AFS, soglasno mezhdunarodnym diagnosticheskim kriteriyam, otneseny: antitela k kardiolipinu (aKL) i/ili volchanochnyi antikoagulyant (VA), i/ili antitela k β2-glikoproteinu 1 (anti-β2-GP 1). V zavisimosti ot pozitivnosti po aFL rekomendovano stratifitsirovat' bol'nykh AFS po sleduyushchim kategoriyam: I – vyyavlenie bolee odnogo laboratornogo markera (v lyuboi kombinatsii); IIa – tol'ko VA; IIb – tol'ko aKL; IIc – tol'ko anti-β2-GP 1 [2]
About the Authors
E. V. Ostryakova
katerina.ostryakova@yandex.ru
N. L. Patrusheva
A. P. Aleksankin
L. I. Patrushev
N. V. Seredavkina
E. N. Aleksandrova
A. V. Volkov
T. M. Reshetnyak
References
1. <div><p>Антифосфолипидный синдром. Под ред. Е.Л. Насонова. М.: Литтерра, 2004;434 с.</p><p>Антифосфолипидный синдром. Под ред. Е.Л. Насонова. М.: Литтерра, 2004;434 с.</p><p>Myakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006;4:295-306.</p><p>Angles-Cano E. Endothelial damage and hypofibrinolysis in systemic lupus erythematosus. J Thromb Haemost 1989;61(2):322</p><p>Glas-Greenwalt P., Kant K.S., Allen C., Pollak V.E. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus. J Lab Clin Med 1984;104(6):962-76</p><p>Awada H., Barlowatz-Meimor G., Dougados M. et al. Fibrinolysis abnormalities in systemic lupus erythematosus and their relation to vasculitis. J Lab Clin Med 1988;111(2):229-36</p><p>Инфекционные болезни. Под ред. С.Г. Пак. М.: МИА, 2008;87-93.</p><p>Giannakopoulos B., Passam F., Rahgozar S., Krilis S.A. Current concepts on the pathogenesis of the antiphospholipid syndrome. J Blood 2007;109:422-30</p><p>Vega-Ostertag M., Pierangeli S.S. Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets. J Curr Rheumatol Rep 2007;9:190-7</p><p>Pierangeli S.S., Chen P.P., Gonzalez E.B. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. J Curr Opin Hematol 2006;13:366-75</p><p>Koike T., Bohgaki M., Amengual O., Atsumi T. Antiphospholipid antibodies: lessons from the bench. J Autoimmun 2007;28:129-33.</p><p>Harpel P.C., Chang T.S., Verdeber E. Tissue plasminogen activator and urocinase mediates the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin. J Biol Chem 1985;260:4432-40</p><p>Fleury V., Angles-Cano E. Characterization of the binding of plasminogen to fibrin surfase: the role of carboxy-terminal lyses. J Biochemestry 1991;30:7630-8</p><p>Nilsson I.M., Tengborn L. Impaired fibrinolysis: new evidence in relation to thrombosis. J Press (pub.), 1983;273-91</p><p>Sobel B.E., Woodcock-Mitchell J., Schneider D.J. et al. Increased plasminogenactivator inhibitor type 1 in coronary artery atherectomy speciment from type 2 diabetic compared with nondiabetic patients. J Circulation 1998;97:2213-21</p><p>Kaitita K., Schoenhard J.A., Painter C.A. et al. Potential roles of plasminogen-activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibitor. J Mol Cell Cardio 2002;34:617-27</p><p>Forastiero R., Martinuzzo M. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. J Lupus 2008;17:872-7.</p><p>Forastiero R., Martinuzzo M. Antigen specificity and clinical relevance of antiphospholipid syndrome-related autoantibodies. J Curr Rheumatol Rev 2005;1:177-87</p><p>Tassies D., Espinosa G., Munoz-Rodriguez F. et al. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthr Rheum 2000;43:2349-58</p><p>Forastiero R., Martinuzzo M., Adamczuk Y. et al. The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome. J Haematologica 2001;86:735-41.</p><p>Yasuda S., Tsutsumi A., Atsumi T. et al. Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies. J Rheumatol 2002;29:1192-7.</p><p>Wang A.Y.M., Poon P., Lai F. et al. Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. J Kidney International 2001;59:1520-8.</p><p>Кондратьева Л.В., Патрушева Н.Л., Патрушев Л.И. Рецидивы тромбозов и геморрагических осложнений у больных с антифосфолипидным синдромом на фоне терапии варфарином. Тер арх 2010;5:33-9</p><p>Joffe H.V., Xu R., Johnson F.B. et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. J Thromb Haemost 2004;91:1123-8.</p><p>Gage B.F., Lesko L.J. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolys 2008;25:45-51</p></div><br />
Review
For citations:
Ostryakova E.V., Patrusheva N.L., Aleksankin A.P., Patrushev L.I., Seredavkina N.V., Aleksandrova E.N., Volkov A.V., Reshetnyak T.M. GOMOZIGOTNAYa MUTATsIYa V GENE INGIBITORA AKTIVATORA PLAZMINOGENA 1 U PATsIENTOV S ANTIFOSFOLIPIDNYM SINDROMOM. Rheumatology Science and Practice. 2011;49(5):83-88. (In Russ.) https://doi.org/10.14412/1995-4484-2011-1465
Views:
1059
Email this article 